Examination of the usefulness using autologous tumour lysate-pulsed monocyte-derived mature dendritic cell vaccinations for postoperative therapy of oral malignant tumor.

Examination of the usefulness using autologous tumour lysate-pulsed monocyte-derived mature dendritic cell vaccinations for postoperative therapy of oral malignant tumor. - Examination of the usefulness using dendritic cell vaccinations for postoperative therapy of oral malignant cancer.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003545

Enrollment

Registered

2010-04-26

Start date

2010-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

oral malignant cancer

Interventions

dendritic cell vaccine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: operable and resectable selfcarcinoma tissue cuts it by sufficient quantity collection high risk of a recurrence or the metastasis performance status 0 1 2 there are not serious organ derangement

Exclusion criteria

Exclusion criteria: 1.pregnant woman / nursing mother 2.WBC under 2,500, PLT under 50000,Hb under 8,ALT, AST over 100IU 3.drug allergy

Design outcomes

Primary

Measure	Time frame
overall survival	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026